Tests BI 3802876 Tolerability in People With Cirrhosis From MASH
Tests how well BI 3802876 is tolerated in adults with cirrhosis due to MASH.
Key facts
- Who runs it
- Boehringer Ingelheim
- Where
- Arlington, Baltimore, Carrollton, Chandler, Charleston, Colorado Springs, Columbus, Coronado, Dallas, Fort Worth, Houston, Iowa City, Jacksonville, Kansas City, La Mesa, Los Angeles, Miami, Miami Lakes, Montclair, Morehead City, Nashville, New York, Rochester, San Antonio, and University Park, United StatesSee the 27 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 27 Feb 2026
- Expected to end
- 5 Aug 2027
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BI 3802876
- Placebo
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with compensated liver cirrhosis (scarring that still lets the liver work) caused by MASH, a fatty liver disease linked to metabolism. It tests how well BI 3802876 is tolerated.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Compensated MASH cirrhosis, Child-Pugh category A, with no past decompensation event (serious liver failure complications). Diagnosis by liver biopsy, imaging or non-invasive tests, as set out in the record.
- Biomarker or test result
- Some routes in need imaging showing liver fat (FibroScan® CAP ≥288 dB/m or MRI-PDFF ≥5%) and at least 2 metabolic conditions, such as obesity or type 2 diabetes.
Main reasons for not taking part
- Signs of advanced high pressure in the liver veins, such as VCTE ≥30 kPa, varices on endoscopy, or HVPG ≥10 mmHg
- Other causes of liver disease, including alcohol, autoimmune liver disease, or past or present hepatitis B or C
- Past liver transplant, being on the transplant list, or liver cancer (HCC) now or in the past
- MELD score > 12 or INR >1.3, unless due to blood thinners
- Heavy drinking (> 210 g/week in males, > 140 g/week in females) within 1 year before screening
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or female adults ≥18 to ≤75 years of age at the time of screening, and at least the legal age of consent in countries where it is > 18 years
- Patients meeting criteria for Child-Pugh category A without history of previous decompensation event
- Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis diagnosed by 1 of the following:; The most recent liver biopsy (≤ 5 years prior to randomisation) showing cirrhosis with steatohepatitis. There is no evidence for a competing aetiology; Historical biopsy (≤ 5 years prior to randomisation) showed steatohepatitis with F1 to F3 fibrosis, but now with cirrhosis either by NITs or biopsy. There is no evidence of competing aetiology. If there is a current biopsy (≤ 6 months prior to randomisation), and it does not show evidence of steatosis or steatohepatitis, there is at least 1 coexisting or history of metabolic comorbidity; The most recent liver biopsy (≤ 5 years prior to randomisation) showing cirrhosis with steatosis. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including obesity and/or type 2 diabetes mellitus (T2DM). There is no evidence for a competing aetiology; Historical biopsy (≤ 5 years prior to randomisation) showed steatosis, but now with cirrhosis, either by NITs or biopsy. If there is a current biopsy (≤ 6 months prior to randomisation), and it does not show evidence of steatosis or steatohepatitis, there are at least 2 coexisting or history of metabolic comorbidities including obesity and/or T2DM. There is no evidence of competing aetiology; Trial participant with cirrhosis with current or previous imaging showing evidence of steatosis (by liver ultrasound or CT scan or FibroScan® with CAP ≥288 dB/m or MRI-PDFF ≥5%). There is no liver histology available. There are at least 2 coexisting or history of metabolic comorbidities, including obesity and/or T2DM. There is no evidence of competing aetiology; Cryptogenic cirrhosis' (either by NITs or biopsy; not to exceed 20% of trial participants) without current or previous evidence of steatosis by imaging or steatosis/steatohepatitis by histology. There are at least 2 coexisting or history of metabolic comorbidities, including obesity and/or T2DM. There is no evidence of competing aetiology; Further inclusion criteria apply
Who cannot take part
- History of significant alcohol consumption (defined as intake of > 210 g/week in males and > 140 g/week in females on average over a consecutive period of more than 3 months) within 1 year prior to screening
- Other causes of liver disease based on medical history and/or centralized review of liver histology, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis [PBC], primary sclerosing cholangitis [PSC], autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1- antitryspin deficiency
- Chronic viral hepatitis parameters that would be considered exclusionary for the participation in this trial are (hepatitis B and C testing will be done at screening visit):; Hepatitis B virus (HBV): Past or present hepatitis B infection, including a positive hepatitis B surface antigen (HBsAg) and/or detectable HBV Deoxyribonucleic Acid (DNA); Hepatitis C virus (HCV): Past or present hepatitis C infection, including positive hepatitis C antibodies and/or detectable HCV ribonucleic acid (RNA)
- History of liver transplantation or patients listed for liver transplantation
- Suspicion, confirmed diagnosis, or history of Hepatocellular Carcinoma (HCC)
- Model for End-Stage Liver Disease (MELD) score > 12, unless due to therapeutic anti-coagulation
- Patients with clinically significant signs of advanced portal hypertension defined by any of the following:; VCTE ≥30 kPa; VCTE ≥25 kPa and platelets < 150,000/μL; History of esophageal or gastric varices (Grade ≥1) on endoscopy; Hepatic venous pressure gradient (HVPG) ≥10 mmHg
- International Normalized Ratio (INR) >1.3 unless due to therapeutic anticoagulants or laboratory error Further exclusion criteria apply
- Present or past evidence of decompensating events of liver cirrhosis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 1 other country, 1 site
- Texas Clinical Research Institute, LLCArlington, United StatesContact: Boehringer IngelheimTaking people
- Johns Hopkins HospitalBaltimore, United StatesContact: Boehringer IngelheimNot yet recruiting
- Epic Medical Research - CarrolltonCarrollton, United StatesContact: Boehringer IngelheimTaking people
- Arizona Clinical Trials - ChandlerChandler, United StatesContact: Boehringer IngelheimTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Boehringer IngelheimTaking people
- Peak Gastroenterology AssociatesColorado Springs, United StatesContact: Boehringer IngelheimTaking people
- Centricity Research Columbus Georgia MultispecialtyColumbus, United StatesContact: Boehringer IngelheimTaking people
- Southern California Research CenterCoronado, United StatesContact: Boehringer IngelheimTaking people
- Baylor Scott & White Research InstituteDallas, United StatesContact: Boehringer IngelheimNot yet recruiting
- The Liver Institute at Methodist DallasDallas, United StatesContact: Boehringer IngelheimTaking people
- Epic Medical Research - Fort WorthFort Worth, United StatesContact: Boehringer IngelheimTaking people
- Houston Methodist HospitalHouston, United StatesContact: Boehringer IngelheimTaking people
- Pioneer Research Solutions, Inc.Houston, United StatesContact: Boehringer IngelheimTaking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Boehringer IngelheimTaking people
- Mayo ClinicJacksonville, United StatesContact: Boehringer IngelheimTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research, San DiegoLa Mesa, United StatesContact: Boehringer IngelheimTaking people
- Kaiser Permanente Los Angeles Medical CenterLos Angeles, United StatesContact: Boehringer IngelheimTaking people
- Schiff Center Liver DiseasesMiami, United StatesContact: Boehringer IngelheimTaking people
- Panax Clinical ResearchMiami Lakes, United StatesContact: Boehringer IngelheimTaking people
- Catalina Research Institute, LLCMontclair, United StatesContact: Boehringer IngelheimTaking people
- Lucas Research, Inc.Morehead City, United StatesContact: Boehringer IngelheimTaking people
- Nashville General HospitalNashville, United StatesContact: Boehringer IngelheimTaking people
- Columbia University Medical CenterNew York, United StatesContact: Boehringer IngelheimTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: Boehringer IngelheimTaking people
- American Research Corporation at the Texas Liver InstituteSan Antonio, United StatesContact: Boehringer IngelheimTaking people
- Covenant Metabolic Specialists, LLC - University ParkUniversity Park, United StatesContact: Boehringer IngelheimTaking people
About the trial
What the trial wants to find out
This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition.
Read full original descriptionShow less
Participants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein.
Participants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.
The 4 groups in the trial
- Placebo groupPlacebo, for comparison
Treatment: Placebo
- Dose group 1Treatment being tested
Treatment: BI 3802876
- Dose group 2Treatment being tested
Treatment: BI 3802876
- Dose group 3Treatment being tested
Treatment: BI 3802876
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Plain-language title
- Tests BI 3802876 Tolerability in People With Cirrhosis From MASHGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07325526, who can take part
- Record updated
- 12 November 2026